Unknown

Dataset Information

0

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial.


ABSTRACT: Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP. It induces migraine-like attacks in migraine patients. Whether the cilostazol model responds to sumatriptan in migraine patients and therefore is valid for testing of future anti-migraine medications has never been investigated.In a cross-over study, 30 patients received cilostazol (200 mg p.o.) on two separate days each day followed by oral self-administered placebo or sumatriptan 50 mg. We recorded headache characteristics and associated symptoms using a questionnaire. The 30 participants were asked to subsequently treat their spontaneous attacks with sumatriptan (50 mg) or placebo in a double-blind cross-over design and 15 participants did so.Cilostazol induced headache with some migraine characteristics in all participants; 18 patients on the sumatriptan day and 19 patients on the placebo day fulfilled criteria for a migraine-like attack. The difference in median headache intensity between sumatriptan and placebo at 2 h was not significant (p?=?0.09), but it was at 4 h (p?=?0.017). During spontaneous attacks, the difference between placebo and sumatriptan was not significant at 2 h (p?=?0.26), but it was highly significant at 4 h (p?=?0.006).The cilostazol model in migraine patients could not be validated by a sufficient sumatriptan response. The model may perhaps respond to new drugs that act intracellularly or directly on ion channels.The study is registered on clinicaltrials.gov ( NCT02486276 ).

SUBMITTER: Falkenberg K 

PROVIDER: S-EPMC5796931 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6097976 | BioStudies
2016-01-01 | S-EPMC4822712 | BioStudies
2015-01-01 | S-EPMC4682470 | BioStudies
2015-01-01 | S-EPMC4320758 | BioStudies
2016-01-01 | S-EPMC4913404 | BioStudies
2017-01-01 | S-EPMC5332324 | BioStudies
2016-01-01 | S-EPMC5036209 | BioStudies
2018-01-01 | S-EPMC6143119 | BioStudies
2012-01-01 | S-EPMC3274575 | BioStudies
2017-01-01 | S-EPMC5296269 | BioStudies